MSRB1 and cancer: However, there is still a need for more inhibitors, particularly for MsrB1, given the potential therapeutic benefits of enhancing inflammation in certain cases, such as chronic infections, vaccine adjuvants, cancer immunotherapy, and immunocompromised patients [25,26,27,28,29].